DURHAM, N.C., Jan. 8 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) announced today that its common stock has been approved for listing on the NASDAQ Capital Market.
"Moving up from the OTC Bulletin Board to the NASDAQ is a very important milestone for our company," said company chairman and CEO Chris J. Stern. "Being listed on the NASDAQ provides us with greater visibility for our company, more liquidity for our stock and the opportunity to further expand our investor base. I believe that this move will deliver increased value for our shareholders now and down the road."
Trading on the NASDAQ is excepted to begin next week. The company will announce further details in due course. Prior to the listing change, Oxygen Biotherapeutics, Inc. shares will continue to trade on the Over-the-Counter (OTC) Bulletin Board.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.
SOURCE Oxygen Biotherapeutics, Inc.